usdaed

These are leveraged ETFs, and they operate on a principle that, while not exactly arcane, is best approached with a degree of cautious skepticism. You can find them offered by firms like Leverage Shares, Direxion, and ProShares. Historically, they’ve tended to latch onto broad market indices, like the S&P 500, offering products like the Direxion Daily S&P 500 Bull 3X Shares (SPXL +2.06%). Though, in a display of typical financial ingenuity, they’ve expanded to encompass sectors – ProShares Ultra Financials (UYG +1.41%) being a prime example – and, rather astonishingly, even individual stocks. There’s a 2X Long OPEN Daily ETF (OPEG +14.52%) tracking Opendoor Technologies, for goodness sake! They’ve even managed to create ETFs based on volatility itself – the 2x Long VIX Futures ETF (UVIX 4.53%) – which feels a bit like trying to bottle smoke.

The transaction, recorded on February 17th, 2026, involved the purchase of 4,415,514 shares. The total value of Redmile’s position in Nurix now represents a rather substantial 11.31% of their $1.358 billion in reported assets. One pictures the portfolio managers, meticulously arranging their holdings like specimens in a cabinet, occasionally daring to favour one over another. Their top five holdings, as of the filing, are as follows:

But the land is full of whispers, of catalysts that might yet lift XRP. The question isn’t if it could rise, but if the bargain price of $1.45 holds any real weight, or if it’s just another mirage in this sun-baked market.

Johnson & Johnson. JNJ. They’ve been handing out dividends for a long time. Over fifty years. That’s…a lot of years. They call them a Dividend King. Kings fall, of course. But this one seems pretty sturdy. So it goes.

According to the latest filings – those bureaucratic pronouncements that arrive with the regularity of a tax collector – Redmile increased its stake in Immunome during the fourth quarter of last year. The transaction, amounting to $12.20 million, swelled the total position by a substantial $64.01 million. A figure that includes not only the newly acquired shares, but also the capricious whims of the market. One must remember, the stock market is a fickle mistress, prone to sudden changes of heart.

They reduced their stake by 3,214,096 shares, bringing Zymeworks down to a measly 0.95% of their portfolio. Less than 1%. It’s the financial equivalent of ghosting. They’re not completely abandoning ship – they still have a little skin in the game – but they’ve definitely moved to a safe distance. The quarter-end value dropped $50.35 million. A tidy sum. It’s a good thing they’re not relying on me for financial advice. I’d have probably invested it all in vintage champagne.

According to a filing with the Securities and Exchange Commission – a document, I confess, that usually sends me reaching for a bracing cup of tea – Redmile Group has increased its stake in Krystal Biotech. This wasn’t merely a nibble at the stock, mind you, but a substantial addition, calculated at the aforementioned $3.43 million, based on the average closing price for the final quarter of 2025. The total value of Redmile’s investment, as of quarter’s end, has swelled by $50.33 million, a consequence of both shrewd purchasing and the stock’s pleasing upward climb.

One is compelled to inquire: is this a venture worthy of capital, or merely another ephemeral bubble in the ever-restless sea of speculation? Let us consider the matter with a degree of circumspection.

Apparently, this Redmile group—they’re increasing their position in Scholar Rock. By a lot. $49.37 million. And the value of their existing shares also went up $84.58 million. It’s just…excessive. Like ordering a side of guacamole when you already know you’re going to spill it on your shirt. It’s tempting fate. And then they expect gratitude? For throwing money at a biotech company?